Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The first patient has been dosed in a clinical trial to explore whether or not Eisai’s eribulin in combination with Halozyme Therapeutics’ PEGPH20 can improve overall response rate (ORR) in women with advanced breast cancer.
Subscribe to our email newsletter
The collaborative phase 1b/2 clinical trial will evaluate whether the combination is beneficial to ORR in patients diagnosed with High-Hyaluronan (HA) human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
The study protocol includes metastatic HER2-negative patients with HA-high breast cancer that were previously untreated and those that received one prior line of therapy.
PEGPH20 is an investigational drug administered intravenously to target the degradation of HA, a glycosaminoglycan that can accumulate around cancer cells to inhibit other therapies.
Eribulin is a microtubule dynamics inhibitor that is believed to work primarily through a tubulin-based mechanism that causes prolonged and irreversible mitotic blockage, leading to apoptotic cell death.
In HA-high triple-negative breast preclinical animal models, the addition of PEGPH20 to eribulin demonstrated a significant increase in tumor growth inhibition and overall tumor regression when compared to eribulin alone.
Halozyme Therapeutics president and CEO Helen Torley said: "Initiation of this study is not only a major milestone in our collaboration with Eisai, it underscores our combined focus on advancing the treatment of metastatic breast cancer—one of the most common cancers in women worldwide.”